# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Joseph Pantginis maintains Actinium Pharma (AMEX:ATNM) with a Buy and lowers the price targe...
Actinium Pharmaceuticals (AMEX:ATNM) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate o...
Maxim Group analyst Jason McCarthy maintains Actinium Pharma (AMEX:ATNM) with a Buy and lowers the price target from $30 to $5.
FDA rejects Actinium Pharmaceuticals' Phase 3 SIERRA trial for Iomab-B's Biologics License Application due to inadequat...
Additional head-to-head randomized clinical trial demonstrating overall survival benefit with Iomab-B is required by FDA to sup...